Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome.

ClinicalTrials.gov ID: NCT00401830

Public ClinicalTrials.gov record NCT00401830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 400 mg/Day Lacosamide Tablets in Subjects With Signs and Symptoms Associated With Fibromyalgia Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial investigated the efficacy and safety of 400mg/day of lacosamide as compared to placebo in reducing the signs and symptoms of fibromyalgia syndrome.

Study identification

NCT ID: NCT00401830
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: UCB Pharma; Industry
Enrollment: 159 participants

Conditions and interventions

Conditions

Fibromyalgia Syndrome

Interventions

Lacosamide Drug
Placebo Other

Drug · Other

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 30, 2006
Primary completion: Jan 31, 2008
Completion: Jan 31, 2008
Last update posted: Jul 17, 2018

2006 – 2008

United States locations

U.S. sites: 25
U.S. states: 16
U.S. cities: 24

Facility	City	State	ZIP	Site status
Not listed	Litchfield Park	Arizona	—	—
Not listed	Santa Ana	California	92705	—
Not listed	Walnut Creek	California	94598	—
Not listed	Deerfield Beach	Florida	33064	—
Not listed	Fort Lauderdale	Florida	33334	—
Not listed	Fort Myers	Florida	33916	—
Not listed	Tampa	Florida	33614	—
Not listed	Athens	Georgia	—	—
Not listed	Decatur	Georgia	30033	—
Not listed	Peoria	Illinois	61614	—
Not listed	Evansville	Indiana	47714	—
Not listed	Madisonville	Kentucky	42431	—
Not listed	Columbia	Maryland	21045	—
Not listed	Frederick	Maryland	21702	—
Not listed	Brockton	Massachusetts	20301	—
Not listed	Charlotte	North Carolina	28210	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Mogadore	Ohio	44260	—
Not listed	Toledo	Ohio	43623	—
Not listed	Goose Creek	South Carolina	29445	—
Not listed	Memphis	Tennessee	30033	—
Not listed	San Antonio	Texas	78213	—
Not listed	San Antonio	Texas	—	—
Not listed	Richmond	Virginia	23294	—
Not listed	Kirkland	Washington	98033	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00401830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 17, 2018 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00401830 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →